The funding was led by T. Rowe Price and will be used by Quanterix to develop new instruments, expand the firm's assay menu, and other things.
ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.
The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.
Three new investors joined existing investors in leading the round, which will fund desktop instrument development, international sales, and assay menu expansion.
As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.
The firm has signed an exclusive agreement for China with Cold Spring Biotech and a deal for Singapore, Thailand, and Malaysia with Research Instruments.
The firm has re-engineered hardware and redesigned software to improve its single-molecule array platform and has increased its multiplexing capabilities.
Quanterix has won a second GE NFL Head Health Challenge I grant and will use it to develop diagnostics with biomarkers discovered under the first grant.
Leveraging Quanterix's Simoa technology, PBL will be able to enter new markets and strengthen its current product offerings.
The genome editing nucleases slide and hop along double-stranded DNA to find and bind to their target sequence.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.